Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13,498Revenue $M548Net Margin (%)-18.9Z-Score8.8
Enterprise Value $M13,488EPS $-1.3Operating Margin %-13.0F-Score5
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-17.8Higher ROA y-yY
Price/Book9.010-y EBITDA Growth Rate %0Quick Ratio4.2Cash flow > EarningsY
Price/Sales19.95-y EBITDA Growth Rate %0Current Ratio5.2Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-5.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-9.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M147ROI % (ttm)-9.2Gross Margin Increase y-yY

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNJohn Griffin 2014-09-30 Add0.11%$55.78 - $73
($65.82)
$ 91.5339%Add 6.19%2,230,000
BMRNJoel Greenblatt 2014-09-30 Buy $55.78 - $73
($65.82)
$ 91.5339%New holding, 3885 sh.3,885
BMRNFrank Sands 2014-06-30 Add0.35%$56.15 - $68.61
($60.38)
$ 91.5352%Add 22.47%11,925,248
BMRNRay Dalio 2014-06-30 Sold Out -0.03%$56.15 - $68.61
($60.38)
$ 91.5352%Sold Out0
BMRNJohn Burbank 2014-06-30 Sold Out -0.01%$56.15 - $68.61
($60.38)
$ 91.5352%Sold Out0
BMRNRay Dalio 2014-03-31 Buy 0.03%$64.99 - $83.28
($73.66)
$ 91.5324%New holding, 48400 sh.48,400
BMRNJohn Burbank 2014-03-31 Buy 0.01%$64.99 - $83.28
($73.66)
$ 91.5324%New holding, 5173 sh.5,173
BMRNJohn Griffin 2013-12-31 Add0.23%$59.3 - $75.09
($67.74)
$ 91.5335%Add 17.71%2,060,000
BMRNFrank Sands 2013-09-30 Reduce-0.2%$58.64 - $78.388
($66.48)
$ 91.5338%Reduce -9.49%10,268,812
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 91.5347%Sold Out0
BMRNFrank Sands 2013-03-31 Add0.24%$49.2 - $62.39
($56.51)
$ 91.5362%Add 10.9%10,951,298
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 91.5362%Reduce -69.03%40,700
BMRNFrank Sands 2012-12-31 Add1.56%$36.78 - $50.17
($45.59)
$ 91.53101%Add 450.74%9,874,728
BMRNDaniel Loeb 2012-12-31 Sold Out -0.79%$36.78 - $50.17
($45.59)
$ 91.53101%Sold Out0
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 91.53101%Reduce -60.99%131,400
BMRNJohn Griffin 2012-12-31 Reduce-0.28%$36.78 - $50.17
($45.59)
$ 91.53101%Reduce -20.09%1,750,000
BMRNJohn Griffin 2012-09-30 Buy 1.4%$37.23 - $43.29
($39.41)
$ 91.53132%New holding, 2190000 sh.2,190,000
BMRNDaniel Loeb 2012-09-30 Buy 0.79%$37.23 - $43.29
($39.41)
$ 91.53132%New holding, 1000000 sh.1,000,000
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 91.53154%Sold Out0
BMRNAndreas Halvorsen 2012-06-30 Sold Out -0.12%$32.53 - $38.87
($36.01)
$ 91.53154%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these Gurus:


News about BMRN:

Articles On GuruFocus.com
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 
BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 11,250 Shares Nov 24 2010 

More From Other Websites
5:45 am Biomarin Pharm announce expiration of the Hart-Scott-Rodino waiting period for BioMarin's... Dec 26 2014
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's... Dec 24 2014
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's... Dec 24 2014
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 23 2014
BioMarin CEO Sees Big Future For Prosensa Drug Dec 23 2014
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015 Dec 22 2014
PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Dec 12 2014
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement Dec 10 2014
BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome Dec 10 2014
FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of... Dec 10 2014
BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome Dec 10 2014
FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of... Dec 10 2014
BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on... Dec 09 2014
BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on... Dec 09 2014
BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome Dec 07 2014
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta Dec 05 2014
Rare disease biotech deal Dec 03 2014
BioMarin to Host Analyst and Investor Day on December 10th in New York Dec 03 2014
BioMarin to Host Analyst and Investor Day on December 10th in New York Dec 03 2014
Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES Dec 03 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK